KLK3 and prostate carcinoma: Yamamoto et al. investigated brachytherapy-treated prostate cancer tissues and found that anti-tumor immune responses, coupled with the therapeutic effect of radiation on the tumor, are responsible for the disease unrelated, post-treatment elevation of prostate-specific antigen [49].